Roche’s market capitalisation growth of 13.8% was driven by FDA approvals for two key products in September 2024: Ocrevus ...

TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million ...

Over the last 7 days, the United States market has dropped 1.6%, yet it remains up by an impressive 30% over the past year, with earnings forecasted to grow by 15% annually. In this dynamic ...

As of now, Halozyme’s stock has delivered a YTD performance of +36.82%, outpacing the S&P 500’s +19.62% return. This stark contrast not only showcases Halozyme’s exceptional growth but also emphasizes ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results ...

A second Trump term has implications for issues including trade, defence and the shared border Three people have been arrested and charged over an incident at a Hindu temple near Toronto. Justice ...

Roche's key products like Vabysmo, Ocrevus, and Phesgo are performing well. Read why RHHBY stock looks well positioned to ...

FRANKFURT: The CEO of pharmaceuticals giant Roche, opens new tab said authorities should block the takeover of contract drug manufacturer Catalent, opens new tab by Novo Nordisk's controlling ...

The FDA also approved Ocrevus Zunovo as the first and only twice-a-year 10-minute subcutaneous injection for patients with relapsing and progressive multiple sclerosis. The European Commission ...

Dubbed Ocrevus Zunovo, the under-the-skin version of the blockbuster CD20 antibody drug could represent an additional CHF 2 billion sales opportunity, Graham said during the investor call.

Vabysmo (eye diseases) was the biggest growth driver of sales, with Phesgo (breast cancer), Ocrevus (multiple sclerosis), Hemlibra (hemophilia) and Polivy (blood cancer) being the other ...